Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Rystiggo UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia
Product name
Rystiggo
Accepted date
Nov-2023
Active ingredients
rozanolixizumab
Proposed indication
For the treatment of generalised myasthenia gravis (gMG).
Application type
A (new medicine)
Publication date
Nov-2023